Eliglustat (Genz 99067) | Glucocerebroside Synthase Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	491833-29-5
Formula :	C₂₃H₃₆N₂O₄
M.W :	404.54
SMILES Code :	CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](C2=CC=C(OCCO3)C3=C2)O)=O
Synonyms :	Genz 99067; GENZ-112638
MDL No. :	MFCD19443735
InChI Key :	FJZZPCZKBUKGGU-AUSIDOKSSA-N
Pubchem ID :	23652731

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Madin-Darby canine kidney (MDCK) cells	1 μM	1 hour	To assess the inhibitory activity of compounds against glucosylceramide synthase	PMC7919060
LP-1 cells	30 μM	24 hours	To evaluate the effect of Eliglustat on cells lacking P-glycoprotein expression. Results showed that Eliglustat alone at high concentration reduced cell viability but did not show synergy with proteasome inhibitors.	PMC8033612
KMS-18 cells	30 μM	24 hours	To evaluate the effect of Eliglustat on P-glycoprotein activity and its synergy with proteasome inhibitors. Results showed that Eliglustat at high concentration (30 μM) synergized with proteasome inhibitors to increase cell death but did not significantly inhibit P-glycoprotein activity.	PMC8033612
WT-MDCKII and MDR1-MDCKII cells	0, 1, 3, 10, 30, 100, 300 nM	24 hours	Evaluate the activity of GCS inhibitors in intact cells	PMC3269155
SF8628 cells	5 µM, 20 µM, 40 µM	24 hours	To assess the effect of Eliglustat on GD2 expression. 40 µM Eliglustat significantly reduced the percentage of GD2-positive cells and GD2 mean intensity.	PMC10298524
Human blood outgrowth endothelial cells (BOECs)	8.0 nM	24 hours	To investigate the effect of Eliglustat on Stx-B binding to the endothelial cell surface. Results showed that Eliglustat significantly reduced Stx-B binding to the cell surface.	PMC8537462
Primary human glomerular microvascular endothelial cells (HGMVECs)	8.0 nM	24 hours	To investigate the effect of Eliglustat on Stx-B binding to the endothelial cell surface. Results showed that Eliglustat significantly reduced Stx-B binding to the cell surface.	PMC8537462
EA.hy926 human endothelial cell line	200 nM	3 days	To study the effect of eliglustat on VWF secretion, it was found that eliglustat treatment slightly but significantly increased VWF secretion from both CR-WT and CR-GLA cells.	PMC6320285
PC-3M	128 µM	48 hours	To evaluate the effect of Eliglustat on prostate cancer cell viability, showing dose-dependent cytotoxicity	PMC7453025
RM-9	128 µM	48 hours	To evaluate the effect of Eliglustat on prostate cancer cell viability, showing dose-dependent cytotoxicity	PMC7453025
RAW264.7 cells	0.1, 1, 10, 25, 50 μM	5 days	Eliglustat inhibited TRAP-positive OC formation in a dose-dependent manner	PMC9780346
PC-3M	128 µM	6 hours	To evaluate the effect of Eliglustat on lipid metabolism, showing accumulation of intracellular ceramides and reductions in glycosphingolipids	PMC7453025
SF8628 cells	100 µM	72 hours	To assess the effect of Miglustat on GSL expression by mass spectrometry. 100 µM Miglustat significantly reduced the expression of five gangliosides (GM3, GM2, GM1, GD3, GD2) and neutral GSL.	PMC10298524
SF8628 cells	100 µM	72 hours	To assess the effect of Miglustat on GD2 expression. 100 µM Miglustat slightly but significantly reduced the percentage of GD2-positive cells and GD2 intensity after 72 hours.	PMC10298524
SF8628 cells	5 µM	72 hours	To assess the long-term effect of Eliglustat on GD2 expression. 5 µM Eliglustat significantly reduced the percentage of GD2-positive cells and GD2 intensity after 72 hours.	PMC10298524
SW480 cells	100 nmol		Inhibited UGCG-mediated ceramide glycosylation, reversed ECHS1-induced suppression of PI3K/Akt/mTOR pathway and expression of autophagy-related proteins	PMC8494735
HCT116 cells	100 nmol		Inhibited UGCG-mediated ceramide glycosylation, reversed ECHS1-induced activation of PI3K/Akt/mTOR pathway and expression of autophagy-related proteins	PMC8494735

Rats	Sprague Dawley rats	Oral	10 mg/kg	Single dose	To investigate the effects of amiodarone and quinidine on the metabolism of Eliglustat. Results showed that amiodarone and quinidine significantly increased the main pharmacokinetic parameters (AUC0→t, AUC0→∞, and Cmax) of eliglustat and decreased clearance obviously.	PMC6913762
Mice	C57BL/6 mice	Intraperitoneal injection	10 mg/kg	Once daily for 3 days	To evaluate the effect of the compound on brain glucosylceramide levels	PMC7919060
C57BL/6 mice	Wild-type mice	Intraperitoneal injection	10 mg/kg/day	Once daily for 3 days	Evaluate the effect of 3h on brain GlcCer levels	PMC3269155
C57BL/6J mice	Healthy mice	Chow	150 mg/kg/day	19 days	Eliglustat increased trabecular bone volume by inhibiting OCs	PMC9780346
C57BL/6N mice	RM-9-luciferase prostate cancer model	Intraperitoneal injection	60 mg/kg	Once daily for 15 days	To evaluate the effect of Eliglustat on prostate cancer tumor growth, showing suppression of tumor growth	PMC7453025
BALB/c nude mice	Subcutaneous tumor model	Intraperitoneal injection	60 mg/kg	Daily for four weeks	Reversed ECHS1-induced oxaliplatin resistance and subcutaneous tumor growth	PMC8494735

{[proInfo.proName]}

CAS No.: 491833-29-5

{[proInfo.proName]}

CAS No.: 491833-29-5

Alternative Products

Product Details of Eliglustat

Safety of Eliglustat

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01074944	Gaucher Disease	Phase 3	Completed	-	-
NCT00358150	Gaucher Disease, Type 1 ... More >> Cerebroside Lipidosis Syndrome Glucocerebrosidase Deficiency Disease Glucosylceramide Beta-Glucosidase Deficiency Disease Gaucher Disease, Non-Neuronopathic Form Less <<	Phase 2	Completed	-	United States, New York ... More >> New York University New York, New York, United States New York, New York, United States Argentina Aprillus Asistencia e Investigación Buenos Aires, Argentina Hospital de Oncologia Maria Curie Buenos Aires, Argentina IMAI Buenos Aires, Argentina Instituto Argentino de Diagnostico y Tratamiento (IADT) Buenos Aires, Argentina Buenos Aires, Argentina Hospital Ramos Mejia Ciudad Autonoma de Buenos Aires, Argentina Israel Rambam Medical Center Haifa, Israel Haifa, Israel Sha'are Zedek Medical Centre Jerusalem, Israel Jerusalem, Israel Italy Universita degli Studi di Milano Milano, Italy Mexico Instituto Mexicano del Seguro Social D.f., Mexico Mexico City, Mexico Russian Federation Hematology Research Center of Ministry of Healthcare of the Russian Federation Moscow, Russian Federation Moscow, Russian Federation Less <<
NCT00943111	-		Completed	-	-
NCT01074944	-		Completed	-	-
NCT00891202	-		Completed	-	-
NCT00891202	Gaucher Disease, Type 1	Phase 3	Completed	-	United States, California ... More >> UCSF MS Center San Francisco, California, United States, 94143 United States, Connecticut Yale University School of Medicine New Haven, Connecticut, United States, 06510 United States, Georgia Emory University Medical Genetics Decatur, Georgia, United States, 30033 United States, Kansas University of Kansas Medical Center, Division of Hematology/Oncology, Dept. of Medicine Westwood, Kansas, United States, 66160 United States, New York New York University School of Medicine, Neurology Department New York, New York, United States, 10016 Mount Sinai School of Medicine New York, New York, United States, 10029 Bulgaria University hospital "Alexandrovska" Sofia Sofia, Bulgaria, 1431 Canada Sir Mortimer B. Davis - Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 Mount Sinai Hospital and the Samuel Lunenfeld Research Institute Toronto Ontario, Canada, M5G 1X5 Colombia Hospital de San Jose Bogota, Colombia India Christian Medical College Hospital Vellore, India, 632004 Israel Rabin Medical Center, Beilinson Hospital Petach Tikvah, Israel, 49100 Lebanon Hôtel-Dieu de France University Hospital Beirut, Lebanon Mexico OCA Hospital Monterrey, Nuevo Leon, Mexico Russian Federation Hematology Research Center of Ministry of Healthcare of the Russian Federation Moscow, Russian Federation, 125167 Serbia Institut za endokrinologiju Belgrade, Serbia, 11000 Tunisia Hopital La-Rabta Tunis, TN, Tunisia, 1007 United Kingdom Royal Free Hospital London, United Kingdom, NW3 2QG Less <<
NCT02536937	Gaucher Disease	Phase 1	Completed	-	United States, Florida ... More >> Investigational Site Number 840004 Miami, Florida, United States, 33014 United States, Minnesota Investigational Site Number 840002 St. Paul, Minnesota, United States, 55144 United States, Tennessee Investigational Site Number 840001 Knoxville, Tennessee, United States, 37920 Less <<
NCT00943111	Gaucher Disease, Type 1	Phase 3	Completed	-	-
NCT02422654	Gaucher Disease	Phase 1	Completed	-	United States, Indiana ... More >> Investigational Site Number 840001 Evansville, Indiana, United States, 47710 Less <<
NCT02536911	Gaucher Disease	Phase 1	Completed	-	United States, Florida ... More >> Investigational Site Number 840002 Miami, Florida, United States, 33014 United States, Tennessee Investigational Site Number 840001 Knoxville, Tennessee, United States, 37920 Less <<
NCT01659944	Healthy	Phase 1	Completed	-	United States, Texas ... More >> Austin, Texas, United States Less <<
NCT01357811	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... More >> PPD Phase I Clinic Austin, Texas, United States Less <<
NCT00358150	-		Completed	-	-
NCT01452542	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... More >> PPD Phase 1 Unit Austin, Texas, United States Less <<
NCT02536755	Gaucher's Disease	Phase 3	Enrolling by invitation	June 22, 2021	Canada ... More >> Investigational Site Number 124002 Montreal, Canada, H3T 1E2 Russian Federation Investigational Site Number 643001 Moscow, Russian Federation, 125167 Investigational Site Number 643002 St-Petersburg, Russian Federation, 197341 Less <<
NCT03519646	Gaucher Disease, Type III		COMPLETED	2020-09-11	National Taiwan University Hos... More >>pital, Taipei, 10041, Taiwan Less <<
NCT03485677	Gaucher's Disease Type I ... More >> Gaucher's Disease Type III Less <<	Phase 3	Recruiting	March 2023	Canada ... More >> Investigational Site Number 1240002 Recruiting Calgary, Canada, T3B 6A8 Investigational Site Number 1240001 Recruiting Toronto, Canada, M5G 1X8 Investigational Site Number 1240003 Recruiting Vancouver, Canada, V6H 3V4 Italy Investigational Site Number 3800001 Recruiting Genova, Italy, 16147 Russian Federation Investigational Site Number 6430001 Recruiting Moscow, Russian Federation, 119049 Investigational Site Number 6430004 Recruiting Moscow, Russian Federation, 119991 Investigational Site Number 6430005 Recruiting St-Petersburg, Russian Federation, 197341 Investigational Site Number 6430002 Recruiting Tomsk, Russian Federation, 634050 Turkey Investigational Site Number 7920001 Recruiting Ankara, Turkey, 06500 Investigational Site Number 7920002 Recruiting Izmir, Turkey, 35040 Less <<
NCT06193304	Gaucher's Disease	PHASE1	COMPLETED	2014-09-21	Covance Clinical Researsh Unit... More >>, Evansville, Indiana, 47710, United States Less <<
NCT06188325	Gaucher's Disease	PHASE1	COMPLETED	2018-03-26	M.D.Covance Clinical Research ... More >>Unit 1341 W, Dallas, Texas, 75247, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.47mL 0.49mL 0.25mL	12.36mL 2.47mL 1.24mL	24.72mL 4.94mL 2.47mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed